NEW YORK (GenomeWeb News) – Alliance Global today said that it has signed an agreement with Amgen to provide cancer mutation testing in certain countries in the Middle East and Africa.

The partners have established a program to provide next-generation sequencing-based screening to identify colorectal cancer patients who have mutations in the RAS family of genes. They will utilize Illumina's MiSeqDx platform in screening the patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.